4.2 Article

A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM/BEAM conditioning regimen and autologous stem cell transplantation

Related references

Note: Only part of the references are listed.
Article Oncology

Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

Richard T. Hoppe et al.

Summary: This article discusses the classification and treatment options for Hodgkin lymphoma, focusing on radiation therapy dose constraints and the management of advanced-stage and relapsed or refractory Hodgkin lymphoma.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Article Oncology

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

William G. Wierda et al.

Summary: The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has evolved significantly in recent years, with BTK inhibitors and BCL-2 inhibitors emerging as effective chemotherapy-free options. Undetectable minimal residual disease after treatment is becoming an important predictor of progression-free and overall survival for patients receiving BCL-2 inhibitor-based treatment. This study discusses the updates to the NCCN Guidelines for CLL/SLL, specifically focusing on the use of chemotherapy-free treatment options for both treatment-naive and relapsed/refractory disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Review Immunology

Contribution of Human Thrombospondin-1 to the Pathogenesis of Gram-Positive Bacteria

Ulrike Binsker et al.

JOURNAL OF INNATE IMMUNITY (2019)

Article Biophysics

Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually

J. R. Passweg et al.

BONE MARROW TRANSPLANTATION (2016)